This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Palantir's Growth Story Gets a Goldman Boost: ETFs to Consider
by Yashwardhan Jain
Palantir's rally gains steam as Goldman Sachs turns bullish and Dan Ives names it a top tech pick for 2027. Here we present some ETFs that offer exposure to PLTR.
Company News for May 13, 2021
by Zacks Equity Research
Companies in the news are: TM, LHDX, EYES, CVI
Second Sight Medical Products (EYES) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Apr 1, 2020
by Zacks Equity Research
Companies In The News Are: KNSA, EYEG, VBIV, EYES
Second Sight Medical Products (EYES) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 4.08% and -40.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Second Sight Medical Products (EYES) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products (EYES) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and -49.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Second Sight Medical Products (EYES) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.